39 research outputs found
Efficacy and Safety of Abciximab in Diabetic Patients Who Underwent Percutaneous Coronary Intervention with Thienopyridines Loading: A Meta-Analysis
It has been controversial whether abciximab offered additional benefits for
diabetic patients who underwent percutaneous coronary intervention (PCI)
with thienopyridines loading.MEDLINE, EMBASE, the Cochrane library clinical trials registry, ISI Science
Citation Index, ISI Web of Knowledge and China National Knowledge
Infrastructure (CNKI) were searched, supplemented with manual-screening for
relevant publications. Quantitative meta-analyses were performed to assess
differences between abciximab groups and controls with respect to post-PCI
risk of major cardiac events (MACEs), angiographic restenosis and bleeding
complications.<0.001), whereas major bleedings rate
was similar (RR: 0.83, 95% CI: 0.27–2.57).Concomitant dosing of abciximab and thienopyridines provides no additional
benefit among diabetic patients who underwent PCI; this conclusion, though,
needs further confirmation in larger studies